First Author: G.Yilmaz TURKEY
Co Author(s): M. Aksoy S. Bayar I. Akkoyun
Back to previous
Vitreomacular traction (VMT) syndrome treated with vitrectomy or intravitreal ocriplasmin injection, these procedures can be invasive and costly than intravitreal perfluoropropane (C3F8) gas injection. The purpose of this retrospective study was to evalute the result of intravitreal C3F8 gas injection for treatment of symptomatic VMT sydrome.
In this observational retrospective study nine eyes of eight patients with focal VMTS on spectral domain-optical coherence tomography (SD-OCT) were included.
All patients received an intravitreal injection of 0.2 mL of 100% C3F8. All patients were examine at first day, first week and first month after treatment. Our study outcomes included change in visual acuity, foveal contour and central foveal thickness on the SD-OCT 1 month after treatment.
The mean age of the patients was 67.5±6.4 (range, 59-77), and the mean follow up time was 11.8±5.2 months (range, 8-16). In all patients, VMT was found to be idiopathic. Detachment of traction was observed in 4 (44.4%) and in 3 (33.3%) of 9 eyes at the first week and the first month, respectively. Two eyes (22.2%) with persisted traction required PPV. At the end of follow up, OCT showed normalized foveal contours in 7 eyes (77.7%) and BCVA increased with the mean of 0.1 LogMAR as compared to pre-injection status. Mean BCVA was 0.6±0.1 LogMAR before the injection, while 0.4±0.2 (range, 0.2-0.7) at the third month (p=0.034). At the end of third month, maximum foveal thickness decreased significantly with the mean of 54.6±14.2μ (p=0.041). No complication was noted.
Intravitreal C3F8 injection might be an alternative approach to PPV, with also being minimally invasive technique in patients with symptomatic and persisting VMTS. Future studies are stil required.